---
title: "688197.SH (688197.SH) — 相關新聞"
type: "Symbol"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/quote/688197.SH/news.md"
symbol: "688197.SH"
name: "688197.SH"
parent: "https://longbridge.com/zh-HK/quote/688197.SH.md"
datetime: "2026-03-11T11:25:21.122Z"
locales:
  - [en](https://longbridge.com/en/quote/688197.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688197.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688197.SH/news.md)
---

> 支持的語言: [English](https://longbridge.com/en/quote/688197.SH/news.md) | [简体中文](https://longbridge.com/zh-CN/quote/688197.SH/news.md)


# 688197.SH (688197.SH) — 相關新聞

### [Shouyao Holdings: Chengda Tianqing will pay the company a one-time revenue sharing of RMB 80 million](https://longbridge.com/zh-HK/news/277747141.md)
*2026-03-04T08:32:13.000Z*
> Shouyao Holdings announced that Chengda Tianqing will pay the company a one-time revenue share of RMB 80 million. This p

### [The innovative drug concept shows signs of partial recovery, Asieris hits a 20% limit up](https://longbridge.com/zh-HK/news/277729344.md)
*2026-03-04T05:44:19.000Z*
> In the afternoon, the innovative drug concept showed a partial rebound, with Asieris hitting the 20% daily limit, Allist

### [Nearly 250 A-share companies have released their performance reports, with over 70% experiencing revenue growth. Who has achieved both performance and stock price growth?](https://longbridge.com/zh-HK/news/276991125.md)
*2026-02-26T06:04:15.000Z*
> As of February 25, approximately 250 A-share companies have released their performance reports for 2025, with over 70% o

### [Shouyao Holdings: Core technical staff Mr. Luo Hong retires and leaves office](https://longbridge.com/zh-HK/news/275720896.md)
*2026-02-12T08:09:16.000Z*
> Shouyao Holdings announced that core technical personnel HONGLUO recently retired due to age and will no longer hold any

### [Shouyao Holdings: MAT2A inhibitor SY-9453 has received a notice of approval for clinical drug trials](https://longbridge.com/zh-HK/news/274789411.md)
*2026-02-04T09:42:02.000Z*
> Shouyao Holdings recently received approval from the National Medical Products Administration for clinical trials of SY-

### [Shouyao Holdings: Annual net profit loss of 129 million yuan in 2025](https://longbridge.com/zh-HK/news/274285710.md)
*2026-01-30T09:48:33.000Z*
> Shouyao Holdings announced that the total operating revenue for the year 2025 reached 8.6676 million yuan, an increase o

### [The Ministry of Commerce and 9 other departments: Encourage large pharmaceutical retail chain enterprises to establish dynamic demand forecasting and low inventory warning mechanisms for pharmaceuticals, and strengthen inventory allocation](https://longbridge.com/zh-HK/news/273346701.md)
*2026-01-22T09:05:54.000Z*
> The Ministry of Commerce and 9 other departments issued opinions to promote the high-quality development of the pharmace

### [Shouyao Holdings: Received government subsidies of 60 million yuan](https://longbridge.com/zh-HK/news/270705876.md)
*2025-12-24T08:45:19.000Z*
> On December 24th, Shouyao Holdings announced that the company recently received government subsidy funds of 60 million y

### [Shouyao Holdings plans to issue shares (H shares) overseas and list on the Hong Kong Stock Exchange](https://longbridge.com/zh-HK/news/269502642.md)
*2025-12-12T09:50:05.000Z*
> Shouyao Holdings plans to issue overseas shares (H shares) and list on the Hong Kong Stock Exchange to enhance core comp